GIDRP88 inhibitors constitute a unique class of chemical compounds designed to selectively impede the activity of the GIDRP88 protein. They function by targeting the molecular machinery that regulates the protein's activity, stability, or interactions with other cellular components. These inhibitors are designed based on the understanding of GIDRP88's role within specific cellular pathways, particularly those involved in signal transduction, protein folding, and degradation processes. By binding to the active or allosteric sites of GIDRP88, these molecules can modify the protein's conformation, leading to a reduction in its functional activity. This conformational change can prevent GIDRP88 from interacting with its substrates or from being properly integrated into larger protein complexes, which is crucial for its functional role within the cell. The precision of these inhibitors is a result of extensive research into the structure and function of GIDRP88, enabling the development of compounds that are highly specific to the intended target and that work to disrupt the protein's activity through various biochemical mechanisms.
The efficacy of GIDRP88 inhibitors is linked to their ability to interfere with the protein's regulatory mechanisms. When GIDRP88's regulatory function is compromised, there is a subsequent impact on the downstream pathways that rely on its activity. This cascade effect can lead to the dampening of specific signaling events, which are critical for certain cellular responses. The inhibitors can alter the protein's activity by preventing post-translational modifications that are necessary for its full activation or by blocking the association with co-factors that are required for its function. These targeted actions make GIDRP88 inhibitors a focal point of research, as they offer insights into the fundamental aspects of cellular regulation. By elucidating the precise interactions and effects of these inhibitors on GIDRP88, scientists gain a deeper understanding of the protein's role in the intricate network of cellular processes, while also paving the way for advancements in biochemical research that hinges on the modulation of specific protein functions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits mTOR, which is essential for the PI3K/AKT pathway. Since the PI3K/AKT pathway is implicated in regulating GIDRP88, inhibition of this pathway by rapamycin would result in decreased activity of GIDRP88. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an irreversible inhibitor of PI3K. Inhibition of PI3K prevents the activation of AKT, leading to the inactivation of downstream targets including GIDRP88. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a chemical inhibitor of PI3K, and by blocking PI3K, it subsequently prevents AKT activation and the subsequent downstream signaling that would normally enhance the activity of GIDRP88. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits the phosphorylation and activation of AKT, which is involved in signaling pathways that would otherwise lead to increased activity of GIDRP88. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which is upstream of the PI3K/AKT pathway. Inhibition of this pathway will reduce signaling through GIDRP88. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor which would decrease signaling through the PI3K/AKT pathway, thereby reducing the functional activity of GIDRP88. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that targets both HER2 and EGFR, leading to downregulation of the PI3K/AKT pathway and subsequent reduction in GIDRP88 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a RAF inhibitor which also indirectly inhibits the PI3K/AKT pathway. By doing so, it can decrease the functional activity of GIDRP88. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib inhibits multiple receptor tyrosine kinases, including PDGFR and VEGFR, which are involved in the PI3K/AKT signaling pathway, thus potentially decreasing the activity of GIDRP88. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor that also impacts the PI3K/AKT pathway. Inhibition of this pathway leads to a reduction in GIDRP88 activity. | ||||||